PUBLIC COMPANY
save$INMInMed Pharmaceuticals Inc.
$INM1.3500-0.74%Vancouver, British Columbia, CAupdated 14h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
3
approvals ytd
0
recalls ytd
1
Pipeline(1)
pipeline depth1 products
1Preclinical
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
🐶 Hiring Signal
News
- Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM dealAnother $200M for Mentari: Migraine drug developer Mentari Therapeutics has lined up a second private placement as it works to close its reverse merger with InMed Pharmaceuticals. The Paragon Thera…endpoints · 2mo ago
- A migraine drugmaker heads to the public markets through reverse mergerMentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.biopharma_dive · 4mo ago
Data sources
last refreshed 59m ago
Found something off?
comments(0)
5-min edit window · permanent after that